000304585 001__ 304585
000304585 005__ 20250916115009.0
000304585 0247_ $$2doi$$a10.1016/j.eururo.2025.08.005
000304585 0247_ $$2pmid$$apmid:40945999
000304585 0247_ $$2ISSN$$a0302-2838
000304585 0247_ $$2ISSN$$a1421-993X
000304585 0247_ $$2ISSN$$a1873-7560
000304585 037__ $$aDKFZ-2025-01908
000304585 041__ $$aEnglish
000304585 082__ $$a610
000304585 1001_ $$0P:(DE-HGF)0$$aHerrmann, Ken$$b0
000304585 245__ $$aSPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis.
000304585 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
000304585 3367_ $$2DRIVER$$aarticle
000304585 3367_ $$2DataCite$$aOutput Types/Journal article
000304585 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1757942358_16966
000304585 3367_ $$2BibTeX$$aARTICLE
000304585 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304585 3367_ $$00$$2EndNote$$aJournal Article
000304585 500__ $$aepub
000304585 520__ $$aProstate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is an evolving diagnostic tool for prostate cancer. There is a need to harmonise existing guidelines and reporting recommendations for PSMA PET/CT. The Standardised PSMA PET/CT Analysis and Reporting Consensus (SPARC) project aims to consolidate classifications and recommendations by a multidisciplinary and international group of experts under one cohesive framework, establishing a dynamic and evolving structure for PSMA PET/CT reporting.We employed a cross-sectional iterative process to define opinions and evaluate consensus. Thirty expert panel members, representing diverse specialities and geographic areas, were selected. A methods expert led the design, data collection, and analysis. Five groups of international multidisciplinary prostate cancer experts convened for literature review and formulation of statements on standardised reporting, detection, primary staging, biochemical recurrence, and treatment response. The groups compiled 91 statements for a two-round modified Delphi survey. The 'RAND appropriateness method' was used for the analysis.Consensus increased to 93% between two rounds. The panel endorsed and adopted the following frameworks for reporting of PSMA PET/CT: molecular imaging PSMA for expression level and certainty, miTNM by PROMISE for reporting of PSMA PET/CT, the PRIMARY score for intraprostatic staging, PSMA volume, mean standardised uptake value, and maximum standardised uptake value (SUVmax). There were uncertainty about correlating PSMA PET/CT with conventional imaging risk groups in newly diagnosed metastatic prostate cancer and a lack of agreement that clinical management plans based upon PSMA PET/CT improved outcomes. There was consensus that SUVmax should be reported regionally, rather than reporting a single site. There were insufficient data to standardise a definition of response or progression by PSMA PET/CT.SPARC provides a standardised PSMA PET/CT analysis and reporting consensus to serve as a future reference for PSMA PET/CT reporting. Integration of common PSMA PET reporting criteria under one umbrella improves the explanation of imaging findings between imaging experts and treating clinicians for clinical implementation.
000304585 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000304585 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304585 650_7 $$2Other$$aPositron emission tomography/computed tomography
000304585 650_7 $$2Other$$aProstate cancer
000304585 650_7 $$2Other$$aProstate-specific membrane antigen
000304585 7001_ $$aWalz, Jochen$$b1
000304585 7001_ $$aMacLennan, Steven$$b2
000304585 7001_ $$aBriganti, Alberto$$b3
000304585 7001_ $$aCornford, Philip$$b4
000304585 7001_ $$aCzernin, Johannes$$b5
000304585 7001_ $$aEiber, Matthias$$b6
000304585 7001_ $$aFanti, Stefano$$b7
000304585 7001_ $$0P:(DE-HGF)0$$aFendler, Wolfgang P$$b8
000304585 7001_ $$aFizazi, Karim$$b9
000304585 7001_ $$aGafita, Andrei$$b10
000304585 7001_ $$aGillessen, Silke$$b11
000304585 7001_ $$aGoffin, Karolien$$b12
000304585 7001_ $$0P:(DE-HGF)0$$aHadaschik, Boris$$b13
000304585 7001_ $$aHofman, Michael S$$b14
000304585 7001_ $$aHope, Thomas A$$b15
000304585 7001_ $$aMaurer, Tobias$$b16
000304585 7001_ $$aMorgans, Alicia K$$b17
000304585 7001_ $$aMorris, Michael J$$b18
000304585 7001_ $$aMurphy, Declan G$$b19
000304585 7001_ $$aOprea-Lager, Daniela E$$b20
000304585 7001_ $$aOst, Piet$$b21
000304585 7001_ $$aÓSullivan, Joe M$$b22
000304585 7001_ $$aRouvière, Olivier$$b23
000304585 7001_ $$aSandhu, Shahneen$$b24
000304585 7001_ $$aSartor, Oliver$$b25
000304585 7001_ $$aSathekge, Mike Machaba$$b26
000304585 7001_ $$aTempany, Clare$$b27
000304585 7001_ $$aWitjes, Wim$$b28
000304585 7001_ $$aEmmett, Louise$$b29
000304585 7001_ $$aBjartell, Anders S$$b30
000304585 773__ $$0PERI:(DE-600)1482253-2$$a10.1016/j.eururo.2025.08.005$$gp. S0302283825004828$$pnn$$tEuropean urology$$vnn$$x0302-2838$$y2025
000304585 909CO $$ooai:inrepo02.dkfz.de:304585$$pVDB
000304585 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000304585 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000304585 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000304585 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000304585 9141_ $$y2025
000304585 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2024-12-20$$wger
000304585 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR UROL : 2022$$d2024-12-20
000304585 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-20
000304585 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-20
000304585 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-20
000304585 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-20
000304585 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-20
000304585 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-20
000304585 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-20
000304585 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-20
000304585 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-20
000304585 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-20
000304585 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-20
000304585 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bEUR UROL : 2022$$d2024-12-20
000304585 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000304585 980__ $$ajournal
000304585 980__ $$aVDB
000304585 980__ $$aI:(DE-He78)ED01-20160331
000304585 980__ $$aUNRESTRICTED